Roth MKM lowered the firm’s price target on Creative Medical Technology (CELZ) to $26 from $30 but keeps a Buy rating on the shares after its 10-K release last week. The company’s cash position should fund operations into 2027, while its clinical stage programs in chronic lower back pain and type 2 diabetes are also generating positive initial efficacy and safety results, and the firm looks forward to similar data updates as they become available, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELZ:
- Creative Medical secures FDA clearance for dose escalation in Phase 1/2 trial
- Creative Medical Technology Approves Executive Bonuses
- Creative Medical announces agreements for exercise of warrants
- Creative Medical Technology comments on presidential initiative for IVF access
- Creative Medical announces mid-term follow-up study data from StemSpine study